Pneumococcal conjugate vaccination at birth in a high-risk setting: No evidence for neonatal T-cell tolerance

• DOI: 10.1016/j.vaccine.2011.05.065
• Publication Date: 2011-06-18T16:51:09Z
• Authors: Anita H.J. van de...; William Pomat; Anthony Bosco; Suparat Phuanukoo...; Catherine J. Devitt; Marie A. Nadal-Sims; Peter M. Siba; Peter C. Richmond; Deborah Lehmann; Patrick G. Holt
• Keywords: Pneumococcal Conjugate Vaccine; Conjugate

Concerns about the risk of inducing immune deviation-associated "neonatal tolerance" as described in mice have restricted widespread adoption neonatal vaccination. The aim this study was to demonstrate immunological feasibility pneumococcal conjugate vaccination (PCV) which could potentially protect high-risk infants resource poor countries against severe disease and mortality early critical period life. Papua New Guinean were randomized be vaccinated with 7-valent PCV (7vPCV) at birth, 1 2 months (neonatal group, n = 104) or 1, 3 age (infant 105), not receive 7vPCV all (control 109). Analysis vaccine responses 9 demonstrated persistently higher type-1 (IFN-γ) type-2 (IL-5 IL-13) T-cell protein carrier CRM197 IgG antibody titres serotypes children according either schedule compared unvaccinated children. In a comprehensive immuno-phenotypic analysis age, no differences quantity quality vaccine-specific T cell memory found between vaccinations versus given their first dose one month. Hospitalization rates month life did differ birth not. These findings that is safe associated tolerance. Neonatal immunisation schedules should therefore considered areas where may result improved coverage earliest possible protection death.